FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not ha…

Rybelsus® (semaglutide) tablets 7 mg or 14 mg, the only FDA-approved oral GLP-1 medicine available, now indicated to reduce ...
Open Heart

Causal relevance of clonal haematopoiesis with cardiac disease and adverse remodelling: a Mendelian randomisation study

Background Many observational studies highlight clonal haematopoiesis (CH) as a novel determinant of cardiovascular disease ...
Goldseiten

New Break Increases Moray Property Position Through Acquisition and Staking

New Break Resources Ltd. is pleased to announce that the Company has increased its land position to the west and northwest of its main Moray property through the acquisition of approximately 4,719 ...